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Purpose. WB-MRI is mainly used for tumor detection and surveillance. The purpose of this study is to establish the feasibility
of WB-MRI at 3T for lesion characterization, with DWI/ADC-mapping and contrast-enhanced sequences, in patients with
neurofibromatosis type 2 (NF-2) and schwannomatosis.Materials and Methods. At 3T, WB-MRI was performed in 11 subjects (10
NF-2 and 1 schwannomatosis) with STIR, T1, contrast-enhanced T1, and DWI/ADC mapping (𝑏 = 50, 400, 800 s/mm2).
Two readers reviewed imaging for the presence and character of peripheral lesions. Lesion size and features (signal intensity,
heterogeneity, enhancement characteristics, and ADC values) were recorded. Descriptive statistics were reported. Results. Twenty-
three lesions were identified, with average size of 4.6 ± 2.8 cm. Lesions were characterized as tumors (21/23) or cysts (2/23)
by contrast-enhancement properties (enhancement in tumors, no enhancement in cysts). On T1, tumors were homogeneously
isointense (5/21) or hypointense (16/21); on STIR, tumors were hyperintense and homogeneous (10/21) or heterogeneous (11/21);
on postcontrast T1, tumors enhanced homogeneously (14/21) or heterogeneously (7/21); on DWI, tumor ADC values were variable
(range 0.8–2.7), suggesting variability in intrinsic tumor properties. Conclusion. WB-MRI with quantitative DWI and contrast-
enhanced sequences at 3T is feasible and advances the utility ofWB-MRI not only to include detection, but also to provide additional
metrics for lesion characterization.
1. Introduction
Whole body magnetic resonance imaging (WB-MRI) has
been used for tumor detection in several clinical settings,
primarily for cancer staging and the detection of metastatic
disease (both visceral and bone metastases) [1–8]. A recent
application for WB-MRI includes the detection of peripheral
nerve sheath tumors (PNSTs) and the assessment of tumor
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burden in syndromes with a predominance of multifocal
PNSTs, such as the NF syndromes, including NF-1, NF-2, and
schwannomatosis (SWN) [9–13]. For such applications, a typ-
ical WB-MRI protocol includes noncontrast T1 and short tau
inversion recovery (STIR), and has thus far been performed
utilizing 1.5 Telsa (T) systems with good diagnostic capability.
However, with the development of new therapeutics there
is an increasing demand to measure not only size, but
also the biologic properties of these tumors. In particular,
functional MRI parameters that include molecular, vascu-
lar, and metabolic-based measures are available with diffu-
sion weighted imaging (DWI)/apparent diffusion coefficient
(ADC) mapping and dynamic contrast-enhanced MRI and
may be applicable to assessing tumor biology longitudinally
as well as in response to specific therapies [8, 14]. There are
several reports in the literature regarding the feasibility of
using “functional” WB-DWI in cancer [3–5, 7, 8, 15–26], but
these techniques have not been explored in benign tumors
such as PNSTs.
The purpose of this study is to show the feasibility of
performing functionalWB-MRI at 3T inclusive of traditional
T1-weighted (T1w) and short tau inversion recovery (STIR)
sequences as well as quantitative DWI with ADC mapping
and contrast-enhanced T1-weighted sequences. We hypothe-
sized that WB-DWI and WB-contrast-enhanced sequences
could be successfully performed in greater than 80% of
patients, and offer functional lesional features not provided
by standard WB-STIR and T1w, which is important to the
characterization of peripheral masses.
2. Materials and Methods
2.1. Overview. Institutional review board approval and writ-
ten informed consent were obtained for this prospective
HIPAA-compliant study. WB-MRI at 3T including quantita-
tive DWI with ADC mapping and postcontrast T1-weighted
imaging was performed in 11 patients who met clinical
diagnostic criteria for NF-2 or SWN (Table 1). Image quality
(Table 2), a determinant of study feasibility, was reviewed
by two investigators, and the presence and character (signal,
enhancement characteristics, and ADC values) of peripheral
lesions were recorded.
2.2. Subject Population. Patients who had presented for clin-
ical evaluation to a specialty clinic with possible NF-2 or
SWN were targeted for recruitment by a neurooncologist.
Inclusion criteria were suspected or confirmed NF2 or SWN
patients who were referred for WB-MRI for the assessment
of tumor burden, no contraindication to MRI, and no prior
systemic therapy for NF2 or SWN. Exclusion criteria were
contraindications toMRI and prior systemic therapy for NF2
or SWN.
2.3. WB-MRI Technique. All studies were performed with a
dedicated clinical research 3T scanner (TimTrio, Siemens
Medical Systems,Malvern, PA, USA) using the Total Imaging
Matrix (TIM). This technology enables the application of
multiple phased-array surface coils and receiver channels for
parallel imaging with an increased signal-to-noise ratio in
three spatial directions while acquiring sections of the body
from the head down to the mid femur. This technology
requires no repositioning of the patient during the scan.
The total scan range of 205 cm was obtained by combining
the large field of view (400–500mm) with automatic table
motion. In the coronal plane, four to six areas were scanned.
The WB-MRI protocol (shown in Figure 1) consisted of T1-
weighted sequences (volume interpolated breath-hold exam-
ination (VIBE), TR/TE = 0.88/2/43ms, field of view = 50 ×
50 cm2, matrix = 256 × 256, slice thickness = 2mm), short
tau inversion recovery (STIR, TR/TE = 6640/84ms, field of
view = 50 × 50 cm2, matrix = 256 × 256, slice thickness =
2mm with interpolation), and quantitative DWI (TR/TE =
4100/70ms, 𝑏 = 50, 400, 800 s/mm2, field of view = 50 ×
50 cm2, averages = 4, acceleration factor = 2, slice thickness =
5mm, bandwidth = 1900 kHz, phase encode lines = 24, echo
spacing = 0.64–0.88) with ADC mapping. The acquisition of
different 𝑏-values allowed for the creation of trace ADCmaps
on a pixel-by-pixel basis for quantitative analysis according to
the following equation:
ADC = −
𝑛
∑
𝑖=1
ln (𝑆
𝑖
/𝑆
0
)
𝑏
𝑖
, (1)
where 𝑏
𝑖
= the diffusion gradient values, 𝑏 = 𝛾2𝐺2𝛿2(Δ −
𝛿/3), 𝛾 = gyromagnetic ratio, 𝐺 = gradient strength, 𝛿 =
diffusion gradient duration, Δ = time between diffusion
gradient pulses, 𝑆
0
= 1st image (𝑏 = 0), and 𝑆
𝑖
= 𝑖th image.
TheDWI sequence 𝑏 value of 50 s/mm2 was chosen to reduce
perfusion effects [27] and the remaining two 𝑏 values were
chosen to obtain an accurate ADC measurement.
Subsequently, a postcontrast T1-weighted sequence
(VIBE, TR/TE = 0.88/2/43ms, FOV = 50 × 50 cm2, matrix =
256 × 256, slice thickness = 2mm) was obtained after
intravenous administration of 0.1mmol/kg gadodiamide
contrast agent (Magnevist, Bayer Schering Pharma AG,
Germany). The contrast agent was injected over 10 seconds
with imaging beginning immediately after completion of the
injection. The contrast bolus was immediately followed by
a 20 cc saline flush. Prior to acquisition of the sequences,
whole body shimming was performed. If excessive image
noise was identified at the time of acquisition, localized fast
shimming was performed as needed. Figure 2 is an example
of the need for localized fast shimming that was performed
for improved diagnostic quality.
All T1-weighted imaging, STIR, and postcontrast T1
imaging were acquired in the coronal plane with isotropic
resolution (T1 VIBE) or near-isotropic resolution (STIR),
allowing reconstruction into axial and sagittal planes for
interpretation. All imaging was respiratory-gated using 2D
Prospective Acquisition Correction (PACE) technique to
minimize artifacts related to respiratory motion. Total acqui-
sition time was approximately 50 minutes.
2.4. Image Analysis and Reader Procedures. Two readers, one
with 10 years experience in musculoskeletal imaging and one
with 8 years experience specifically in WB-MRI technique
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Table 1: Subject and lesion characteristics.
Subject Diagnosis Lesiondiagnosis Lesion location
Lesion
size (cm) T1w signal STIR signal
Average ADC
(×10−3mm2/sec)
Contrast-enhancement
pattern
(1) NF-2 PNST Chest 2.2 Hypointense Hyperintense 1.5 ± 0.15 Homogeneous
PNST Abdomen 6.9 Hypointense Hyperintense 1.2 ± 0.17 Homogeneous
(2) NF-2 PNST Pelvis 1.2 Hypointense Hyperintense 1.9 ± 0.13 Homogeneous
PNST Pelvis 1.0 Hypointense Hyperintense 2.2 ± 0.0 Homogeneous
(3) NF-2 PNST Pelvis 8.1 Hypointense Hyperintense 1.4 ± 0.15 Homogeneous
(4) NF-2
Cyst Paraspinal/L-spine 2.2 Hypointense Hyperintense 2.6 ± 0.16 None
Cyst Paraspinal/L-spine 1.5 Hypointense Hyperintense 2.6 ± 0.16 None
PNST T-spine 2.6 Isointense Hyperintense 0.8 ± 0.21 Homogeneous
PNST Thigh 2.6 Isointense Hyperintense 2.2 ± 0.18 Homogeneous
(5) NF-2 PNST Chest 2.2 Hypointense Hyperintense 1.4 ± 0.18 Homogeneous
PNST Chest 2.8 Hypointense Hyperintense 1.2 ± 0.09 Homogeneous
(6) NF-2
PNST Chest 10.2 Hypointense Hyperintense 1.4 ± 0.12 Homogeneous
PNST Abdomen 6.4 Hypointense Hyperintense 1.7 ± 0.22 Homogeneous
PNST Arm 3.5 Hypointense Hyperintense 1.8 ± 0.21 Homogeneous
PNST Thigh 4.2 Hypointense Hyperintense 1.5 ± 0.15 Homogeneous
(7) SWN
PNST Chest 8.2 Isointense Hyperintense 2.7 ± 0.20 Markedlyheterogeneous
PNST Chest 4.5 Isointense Hyperintense 2.7 ± 0.40 Moderatelyheterogeneous
PNST Chest 3.3 Isointense Hyperintense 2.2 ± 0.28 Homogeneous
PNST Abdomen 8.2 Hypointense Hyperintense 1.9 ± 0.55 Moderatelyheterogeneous
PNST Abdomen 8.6 Hypointense Hyperintense 2.5 ± 0.69 Moderatelyheterogeneous
PNST Pelvis 5.3 Hypointense Hyperintense 1.9 ± 0.17 Moderatelyheterogeneous
PNST Thigh 8.1 Hypointense Hyperintense 1.8 ± 0.30 Moderatelyheterogeneous
PNST Thigh 6.5 Hypointense Hyperintense 2.3 ± 0.37 Moderatelyheterogeneous
(8) NF-2 Nolesions
(9) NF-2 Nolesions
(10) NF-2 NoLesions
(11) NF-2 Nolesions
T1w: T1-weighted imaging; STIR: short tau inversion recovery.
and interpretation, reviewed the images in consensus, (for
image quality, lesion detection, and lesion characterization).
All imaging planes were reviewed (coronal as well as recon-
structed axial and sagittal views). First, readers recorded
the diagnostic quality for each study, by body part (chest,
abdomen, pelvis, thighs, thoracic spine, lumbar spine, neck,
and calves and arms if the latter two were included by
imaging).Qualitywas assessed using a semiquantitative scale,
ranging from 1 to 4, with the quality criteria listed in Table 2.
Second, readers reviewed the imaging and recorded
whether peripheral lesions were present or absent, and
whether each lesion was visible on every sequence (T1, STIR,
DWI/ADC map, and postcontrast T1). STIR images were
reviewed first, followed by DWI/ADC maps and then, T1
images with and without contrast. A lesion was defined as
any mass-like abnormality of increased STIR signal and was
subsequently confirmed on T1-weighted andDWI sequences.
Only peripheral lesions greater or equal to 1 cm seen in at least
two planes were recorded for the purpose of this analysis.
DWI and T1-weighted sequences were also reviewed inde-
pendently and readers recordedwhether additional lesions or
incidental abnormalities in other organs were found on these
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(a) (b) (c)
Figure 1:Whole bodyMRI in a patient with NF-2 andmultiple PNSTs, with good diagnostic quality. In (a), whole body STIR (quality ratings
of 4 in all body parts except abdomen rating of 3) shows multiple PNSTs in the arm (vertical arrow), chest (short arrow), and thigh (long
arrow). In (b), corresponding ADC maping (diagnostic quality of 3 in all body parts except in the arm and neck, where there was a rating of
1 in the arm and a rating of 2 in the chest) shows corresponding PNSTs in the chest (short arrow) and thigh (long arrow) with ADC values
of 1.4 and 1.5 × 10−3mm−2, respectively. Lesion in the arm cannot be identified on the ADC map due to poor diagnostic quality in the arm.
In (c), corresponding T1-weighted postcontrast whole body image shows homogeneous enhancement patterns of the chest, right arm, and
thigh PNSTs.
Table 2: Criteria for assessing the diagnostic quality of WB-MRI.
Diagnostic
quality rating Criteria
(1) Nondiagnostic, with artifacts involving greaterthan 75% of the images
(2) Limited, with artifacts involving 25%–75% of theimages
(3) Diagnostic, but with artifacts involving less than25% of the images
(4) Diagnostic, with no appreciable artifacts
sequences. Readers characterized each peripheral mass by
recording whether each lesion met criteria for a PNST
(showed evidence of internal enhancement following con-
trast administration) or a cyst (showed no evidence of
enhancement following contrast administration).
Readers recorded other characteristics of the lesions
including the size, location (chest, abdomen, pelvis, thighs,
thoracic spine, lumbar spine, neck, calves, or arms), shape
(ovoid or irregular), andmargin (well-defined, partly defined,
ill-defined) of each peripheral lesion.The presence or absence
of a target sign, a split fat sign, and perilesional edema were
recorded [28]. Signal characteristics relative to muscle on
T1-weighted images, STIR and contrast-enhanced imaging
(hypointense, isointense, and hyperintense) were recorded
along with degree of heterogeneity (homogeneous and less
than 25% heterogeneous, moderately heterogeneous with
25%–75% heterogeneity, and markedly heterogeneous with
greater than 75% heterogeneity). The presence or absence
of associated muscle denervation (increased intramuscular
signal on STIR or the presence of atrophy on T1-weighted
imaging) was also recorded. The character of the lesion
regarding its relationship to the adjacent nerve (eccentric
or central) was sought and recorded when possible. For
diffusion weighted images; readers assessed the presence or
absence of heterogeneity and the presence or absence of
the target sign on the ADC maps. Minimum, average, and
maximum ADC map values (with standard deviation) were
recorded for each peripheral lesion. The latter was accom-
plished by placement of a region of interest to encompass
as much of the whole lesion as possible, with exclusion of
surrounding tissues. ADC map measurements were made
on one section through the center of the lesion, to avoid
volume averaging artifact. Lesions that were less than 1 cm
were excluded from the analysis.
2.5. Statistical Analysis. Descriptive statistics were reported
regarding subject demographics, image quality for all body
locations, number of lesions, lesion location, and lesion
characteristics on the anatomic and functional sequences
(signal intensity, heterogeneity, the presence or absence of
specific signs described above, and ADC values).
3. Results
Table 3 summarizes the diagnostic quality ratings for each
sequence, by body part. Overall, taking all body parts into
account, including the spine and neck, diagnostic quality was
ISRN Radiology 5
(a) (b)
Figure 2: Whole body STIR images in a patient with NF-2 with large artifacts through the abdomen and pelvis, due to inadequate shimming
of the large field of view (in (a)) after changing “stations.” In (b), localized fast shimming methods were applied and the shimming was
corrected, producing diagnostic quality images.
Table 3: Average diagnostic quality ratings for each body part and
sequence.
Location T1w STIR DWI T1w +contrast
Spine-chest 3.83 3.59 2.08 3.83
Spine-
Abdomen 3.92 3.8 2.92 3.92
Neck 3.92 3.79 1.08 3.92
Chest 4.00 3.56 2.75 4.00
Abdomen 4.00 3.33 3.08 4.00
Pelvis 4.00 3.33 3.08 4.00
Thigh 4.00 3.33 2.83 4.00
Calves 4.0 3.0 3.0 4.0
Arms 3.0 3.0 1.0 3.0
the highest for T1-weighted sequences (mean 3.95±0.36) and
the lowest for DWI (mean 2.53 ± 0.77), across all subjects.
For STIR, diagnostic quality was an average of 3.51 ± 0.50,
with no quality measurement less than 3. Quality measures
were the lowest for the neck and the highest for the abdomen
and pelvis, for all sequences. The calves were incompletely
included in the field of view of 8 subjects (8/10 patients
with NF-2) and the arms were incompletely included in 11
subjects (9/10 patients with NF-2, 1 patient with SWN, and
1 volunteer). An example of shimming artifact that interfered
with the quality of the image is shown in Figure 2.
In Table 1, a summary of subject and lesion characteristics
is given. A total of 23 lesions (median 3.5 cm, range 1.0–
10.2 cm) were identified; no additional lesions were detected
on the T1-weighted or DWI sequences if they were not
detected on STIR. Lesions were present in the chest (𝑛 = 7),
abdomen (𝑛 = 4), pelvis (𝑛 = 4), thighs (𝑛 = 4), arm (𝑛 = 1),
thoracic spine (𝑛 = 1), and lumbar spine (𝑛 = 2).
Lesion diagnosis and character were determined as fol-
lows. On postcontrast T1-weighted images, 21/23 lesions met
criteria for a PNST (enhancement following contrast admin-
istration), while 2/23 met criteria for a cyst (no evidence of
enhancement following contrast administration). Compared
to skeletal muscle on T1-weighted images, cysts were all
homogeneously hypointense, while PNSTs were homoge-
neously isointense (𝑛 = 5/23) or hypointense (𝑛 = 16/23).
On STIR, cysts were homogeneously hyperintense, while
PNSTs were all hyperintense but with variable heterogene-
ity (10 homogeneous, 8 moderately heterogeneous, and 3
markedly heterogeneous). On STIR, the target sign was
present in 6/23 cases, the split fat sign was present in 3/23
cases, and perilesional edema was absent in all cases. Muscle
denervation was present in 2 cases, in the thigh musculature.
In 2/21 tumors, the relationship of the tumor to the adjacent
nerve could be resolved and was eccentric to the nerve; in
all other tumors, the border with the adjacent nerve was not
clearly identified. On postcontrast T1, tumor enhancement
was homogeneous in 14/21,moderately heterogeneous in 6/19,
and markedly heterogeneous in 1/21.
On diffusion weighted images and ADC maps, 23/23
lesions had diagnostic quality to allow evaluation. All cysts
(2/2) were homogeneously hyperintense, while 12/21 PNSTs
were homogeneously hyperintense and 9/21 PNSTs were
moderately heterogeneous in signal intensity. The target sign
was present in 2/21 PNSTs (compared with 6/23 by STIR).
For cysts, the mean minimum ADC map value was 2.4 ±
0 × 10
−3mm2/sec (range 2.4-2.4), the mean average ADC
map value was 2.6 ± 0.16 × 10−3mm2/sec (range 2.6-2.6) and
the mean maximum ADC value was 2.8 ± 0 × 10−3mm2/sec
(range 2.8-2.8). For PNSTs, the mean minimum ADC map
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Figure 3: Whole body STIR, postcontrast T1-weighted, and DWI images with ADC map showing a paraspinal cyst (arrows) which is
hyperintense on the STIR and DWI images, without demonstrable enhancement on the postcontrast image. The addition of contrast-
enhanced sequences to a WB-MRI protocol enables the distinction of cysts from tumors in patients with neurofibromatosis, a distinction
not otherwise possible by STIR and T1 imaging alone. In addition, the ADC value of the cyst was 2.6 × 10−3mm2/sec in this patient, higher
than the peripheral tumors identified in this patient (0.8 and 2.2 × 10−3mm2/sec), suggesting that ADC values may provide an additional
metric for the distinction of cysts and tumors.
value was 1.36 ± 0.46 × 10−3mm2/sec (range 0.8–2.2), the
mean average ADC value was 1.89 ± 0.53 × 10−3mm2/sec
(range 1.2–2.7), and the mean maximum ADC value was
2.66 ± 0.88 × 10
−3mm2/sec (range 1.4–3.9).
Figure 1 shows the subject in whom the arms were
included and a PNST was identified in the arm. Figure 3
illustrates results in a subject with NF-2 who had peripheral
tumors and paraspinal cysts; the cysts could not be distin-
guished from PNSTs on T1 or STIR but were distinguished
by contrast-enhanced T1 and ADC mapping, underscoring
the utility of intravenous contrast andDWI for characterizing
peripheral lesions.
4. Discussion
WB-MRI with quantitative DWI/ADC mapping and
contrast-enhanced sequences at 3T is feasible with high
diagnostic quality in patients with PNSTs. The application of
this technique to patients with NF2 and SWN is promising,
as these additional sequences may advance the utility of
WB-MRI not only to include anatomic detection, but also
provide quantitative metrics for biologic characterization.
The MRI features given by WB-DWI and contrast-enhanced
sequences allow for the characterization of tumor cellularity
and vascular status.
In previous studies of patients with NF syndromes, WB-
MRI was implemented to counteract the need for separate
scans of the chest, abdomen, pelvis, and thighs and has been
utilized for the detection of peripheral tumors and the deter-
mination of disease burden [9, 11–13, 29, 30]. In these studies,
WB-MRI was performed at 1.5T and focused on T1 and STIR
sequences. Mautner et al. additionally implemented WB-
MRI technique with localized contrast-enhanced sequences
at 1.5T in NF-1 patients for the assessment of disease burden
and identification of malignant peripheral nerve sheath
tumors [10].
In this study, we assessed the feasibility of expanding
WB-MRI techniques to incorporate functionalmeasureswith
DWI and ADC mapping as well as contrast-enhancement
properties. The advantages of performing such studies at 3T
include the available increased signal compared with 1.5T,
which affords a trade-off for spatial resolution and the ability
to perform faster acquisitions with isotropic resolution for
the anatomic sequences (VIBE, STIR). Similar acquisitions at
1.5T will require more scanner time and make the scan more
susceptible to motion artifacts. In addition, the increased
signal available at 3T is theoretically advantageous for acquir-
ing DWI, although susceptibility artifacts may occur with
greater frequency at 3T compared with 1.5T [24]. Advances
in shimming techniques and the use of a continuous table
for WB-MRI, rather than separate station acquisitions, will
likely further improve the quality of WB-DWI. In our study
subjects, WB-DWI was acquired with acceptable diagnostic
quality, although, for most cases, artifact at the edge of
the image was present due to the large field of view. For
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the interpretation of peripheral tumor biology with ADC
values in our study, such artifact was not limiting and may
be inconsequential to the majority of patients.
Regarding technical factors for performing 3T functional
WB-MRI, the coronal plane was chosen for all acquisitions as
it inherently combats respiratory motion artifact compared
with the axial plane. In addition, the coronal plane is a
faster acquisition than the axial plane. Since the anatomic
sequence (T1 VIBE, STIR) acquisitions are performed with
isotropic or near-isotropic resolution, the datasets can be
reconstructed into the axial and sagittal planes (as well as
any other oblique plane of interest) with the same resolution
as the original acquisition. For detailing the anatomy, our
WB-MRI protocol offers good spatial resolution (2mm slice
thickness). For DWI, the acquisition is performed at 5mm
thickness to ensure adequate quality; as DWI is a functional
sequence, high spatial resolution is likely less critical. We
have demonstrated in this report that peripheral lesions
were detectable on the anatomic noncontrast T1, STIR, and
postcontrast T1 sequences as well as the DWI sequences and
ADC maps.
Unlike the use ofWB-MRI for tumor detection, the addi-
tion of contrast-enhanced T1 and DWI sequences enables
the characterization of peripheral lesions. First, a common
challenge with noncontrast sequences is the differentiation
of a tumor from a cyst; with the addition of contrast, the
distinction is clear, since tumors enhance with contrast, while
cysts do not. DWI offers a theoretical advantage in this
regard also, as cysts will likely have a higher ADC map value
than tumors given that the ADC is a measure of cellularity.
Furthermore, if intravenous contrast is contraindicated or
cannot be administered, DWI with ADC mapping can serve
as a potentially useful sequence for distinguishing cysts and
tumors. Second, the natural behavior of PNSTs in NF2 and
SWN is variable between and within patients, with some
peripheral tumors having an indolent course and others
having a more aggressive course. With the advent of WB-
DWI and contrast enhancement, metrics are available which
may increase our understanding of tumor biology and the
association with clinical behavior in the peripheral tumors of
these patients. Interestingly, the contrast enhancement pat-
tern in the subject with SWN (moderately and markedly het-
erogeneous lesional enhancement) was different from that of
the subjects with NF2 (homogeneous lesional enhancement),
perhaps reflecting a difference in tumor biology, although
longitudinal data is not available on these subjects at this
time. Third, the features of peripheral tumors by DWI and
contrast-enhanced sequences may ultimately prove useful
for determining response to treatment, by assessing changes
in the ADC values or contrast-enhancement characteristics
following treatment. Currently, only changes in size are used
to identify treatment response in theNF syndromes, butWB-
DWI has been described for the assessment of treatment
response in other disorders such as bone metastases [13, 23,
31, 32], multiple myeloma [33], lymphoma [15, 16], and Rosai-
Dorfman disease [34]. In the patients with NF2 and SWN in
this study, there was great variability in the ADC values of the
peripheral schwannomas, presumably due to the differences
in cellularity and relative proportion of Antoni A and Antoni
B patterns within each schwannoma. At this time, the utility
of WB-DWI and contrast for the assessment of treatment
response in the NF syndromes has not been established,
as longitudinal studies are needed to determine whether
changes in lesional cellularity that may come about following
treatment are detectable by alterations in the ADC values
or contrast-enhancement pattern of a responding peripheral
tumor.
A limitation of this study is in the use of multistation
acquisitions for the performance of WB-MRI, which poten-
tially impacts the quality of shimming and subsequent image
acquisition.Themulti-station acquisition requires shimming
at each station; this has the potential of changing the initial
shim values, which may affect the homogeneity of the field.
Moreover, the incorrect overlap between each station can
lead to “gaps” between major anatomic regions. To overcome
these potential problems, the use of an integrating program
is needed. Finally, the visualization of WB-MRI data can be a
challenge due to the large datasets acquired and methods are
being developed to integrate them into one dataset for ease of
diagnosis, by creating a multiparametric paradigm in which
information from all the sequences is incorporated into one
image [35].
5. Conclusions
In conclusion, WB-MRI is feasible for both tumor detection
and characterization when applied to the PNSTs seen in
patients with NF-2 and SWN. By adding quantitative WB-
DWI and contrast to theWB-MRI protocol,metrics for lesion
characterization are now accessible and may help increase
our comprehension of tumor biology. In turn, WB-MRI
may potentially impact clinical outcome by distinguishing
the biologically variable PNSTs seen in patients with NF
syndromes, potentially impacting decisions for treatment and
monitoring response to treatment.
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